Amgen Inc Stock Price, News & Analysis

Amgen (NASDAQ: AMGN) corrected a typo and announced AmgenNow, a U.S. direct-to-patient program launching for Repatha (evolocumab) on Oct 6, 2025. Repatha will be offered through AmgenNow at a monthly price of $239, described as nearly 60% below the current U.S. list price and the lowest among G-7 countries.

The program is open to all patients including the uninsured, those with high-deductible plans, cash payers, and participants in Medicare and Medicaid; enrolled patients are not subject to insurer step therapy or prior authorization. The announcement cites VESALIUS-CV Phase 3 results showing Repatha reduced major adverse cardiovascular events and notes Repatha has helped more than 5 million patients.

Amgen (NASDAQ:AMGN) announced groundbreaking results from its Phase 3 VESALIUS-CV clinical trial for Repatha (evolocumab). The study met its dual primary endpoints, demonstrating significant cardiovascular event risk reduction in patients without prior heart attack or stroke history.

The landmark trial involved over 12,000 high-risk patients, with 85% on high-intensity or moderate LDL-C reducing therapy, followed for approximately 4.5 years. Repatha becomes the first and only PCSK9 inhibitor to show significant cardiovascular event reduction in both primary and secondary prevention.

This breakthrough follows Repatha's 2015 approval and successful use by over 6.7 million patients globally. The FDA recently expanded Repatha's approved use for adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL-C.

Amgen (NASDAQ: AMGN) has announced a $650 million expansion of its U.S. manufacturing network, focusing on its biologics facility in Juncos, Puerto Rico. The investment will create 750 new jobs, including construction and highly skilled manufacturing positions.

The expansion aims to enhance drug production capacity and integrate advanced technologies. This initiative follows Amgen's substantial investments since 2017, including a $600 million science center in California and manufacturing expansions worth $900 million in Ohio and $1 billion in North Carolina.

The project is supported by tax policies from the Tax Cuts and Jobs Act of 2017 and the One Big Beautiful Bill Act of 2025, reflecting Amgen's $40 billion total investment in U.S. manufacturing and R&D since 2017.

Amgen (NASDAQ: AMGN) and Kyowa Kirin have announced positive top-line results from their Phase 3 ASCEND long-term extension study of rocatinlimab for moderate to severe atopic dermatitis. The study, involving approximately 2,600 patients, evaluated the drug's safety and efficacy over an additional 32 weeks following initial 24-week therapy.

Key findings include a favorable safety profile with low discontinuation rates and less than 1 per 100 patient-years incidence of gastrointestinal ulceration events. The majority of patients who continued rocatinlimab monotherapy, administered every 4 or 8 weeks, demonstrated sustained therapeutic benefits at one year across multiple measures including skin clearance, itch reduction, and disease control.

Amgen (NASDAQ:AMGN) announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference scheduled for September 9, 2025, at 9:15 a.m. ET. The company will be represented by Peter Griffith, Executive Vice President and CFO, and Kave Niksefat, Senior Vice President of Global Marketing and Access.

The presentation will be accessible through a live webcast on Amgen's website (www.amgen.com) under the Investors section and will remain available for replay for at least 90 days following the event.

Amgen (NASDAQ: AMGN) has announced plans to invest over $600 million in a new state-of-the-art center for science and innovation at its Thousand Oaks, California headquarters. The facility will enhance collaboration among researchers, engineers, and scientists, featuring advanced automation and digital capabilities.

The investment is part of Amgen's $40 billion+ commitment to U.S. manufacturing and R&D since 2017, including $5 billion in direct capital expenditures. Construction will begin in Q3 2025, creating hundreds of jobs. This announcement follows recent expansions including a $900 million facility in Ohio and a $1 billion plant in North Carolina.

Amgen (NASDAQ:AMGN) announced its upcoming participation in the 2025 Wells Fargo Healthcare Conference. The presentation will take place on Wednesday, September 3, 2025, at 10:15 a.m. ET. Dr. Paul Burton, the company's Senior Vice President and Chief Medical Officer, will represent Amgen at the conference.

The presentation will be accessible via webcast on Amgen's website under the Investors section, with the recording remaining available for replay for at least 90 days following the event.

Amgen (NASDAQ:AMGN) has received FDA approval for expanded use of Repatha® (evolocumab) to include adults at increased risk of major adverse cardiovascular events (MACE) due to uncontrolled LDL-C. This significant label update removes the previous requirement for patients to have diagnosed cardiovascular disease.

The FDA has also approved Repatha as a monotherapy for patients with homozygous familial hypercholesterolemia (HoFH) and emphasized its use alongside diet and exercise for managing high cholesterol. Since its initial approval in 2015, Repatha has been used by over 5 million people globally.

Amgen (NASDAQ:AMGN) reported strong Q2 2025 financial results with total revenues increasing 9% to $9.2 billion. Product sales grew 9%, driven by 13% volume growth, partially offset by 3% lower net selling price. GAAP EPS increased 92% to $2.65, while non-GAAP EPS rose 21% to $6.02.

Key highlights include fifteen products achieving double-digit sales growth, notably Repatha (+31%), EVENITY (+32%), UPLIZNA (+91%), and TEZSPIRE (+46%). The company generated $1.9 billion in free cash flow and maintained its 2025 revenue guidance of $35.0-36.0 billion.

However, some established products faced challenges, with Enbrel sales declining 34% and Prolia/XGEVA expecting sales erosion due to biosimilar competition in H2 2025.